Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Kyowa Kirin to Draw Up 5-Year Midterm Plan Focusing on Development of Global Products: President Hanai
August 4, 2015
- MTPC Files Edaravone for Amyotrophic Lateral Sclerosis in South Korea
August 4, 2015
- Kyowa Kirin’s Pharma Business Sales Up 13% Driven by New Products, Overseas Business in 1st Half of FY2015
August 3, 2015
- JCR Files for Growject Liquid Formulation
August 3, 2015
- Ono Files Opdivo for Use in Chemotherapy-Naïve Patients
August 3, 2015
- Post-Marketing Study Shows No Causal Relationship of Actos with Bladder Cancer: Takeda
August 3, 2015
- Novartis Files NDA for Acromegaly Treatment Pasireotide in Japan
August 3, 2015
- Bayer Yakuhin Files Nexavar to Expand Indication for Thyroid Cancer
August 3, 2015
- Otsuka Holdings Increases Forecasts for 1st Half of FY2015
August 3, 2015
- Wholesalers Must Ponder Use of Reps for New Business: Mediceo CEO
July 31, 2015
- Nichi-Iko to Tie Up with Thai Drug Maker to Strengthen Lineup, Accelerate Brand Penetration
July 31, 2015
- Nippon Kayaku Initiates PIII Study of Herceptin Biosimilar in Japan
July 31, 2015
- Sumitomo Dainippon’s Leigh Syndrome Drug Showed No Statistical Difference in PIIb Study in US
July 31, 2015
- Cresemba Fails to Meet Primary Endpoint in PIII Study for Candidemia: Astellas
July 31, 2015
- Eisai Files Halaven for Soft Tissue Sarcoma Simultaneously in Japan, US, Europe
July 31, 2015
- Kyowa Kirin Files NDA for Brodalumab for Psoriasis in Japan
July 31, 2015
- Kyowa Kirin, BMS to Collaborate in Study of Combination Poteligeo, Opdivo in US
July 31, 2015
- AbbVie Pres. Says Japan Attracting Foreign Investments, Confident in Hep C Drug
July 31, 2015
- Delving into Securities Filings - 3: Sales Rep Ratio at Drug Makers Up Slightly in FY2014
July 31, 2015
- Series: Delving into Securities Filings
July 31, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…